GlassScriptPhysician profile
Alejandro A Dacanay
NPI 1770194243
$7,765.96
in general payments reported to CMS, 2019-2025
56 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,659 · 2022: $1,554 · 2023: $1,046 · 2024: $1,499 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,953 · Consulting Fee: $500 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,952.96 |
| Consulting Fee | $500.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $918.59 | 2021-2025 | Datroway, Enhertu |
| Novartis Pharmaceuticals Corporation | $707.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $638.40 | 2021-2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $420.12 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pharmacyclics LLC, An Abbvie Company | $322.38 | 2021-2023 | Imbruvica, Epkinly |
| Amgen INC. | $269.87 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Genzyme Corporation | $266.52 | 2021-2025 | |
| Caris Mpi, INC. | $250.04 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $235.89 | 2021-2024 | |
| Seagen INC. | $231.97 | 2021-2023 | Adcetris, Padcev |
| Astellas Pharma US INC | $225.55 | 2021-2024 | Xospata, Padcev |
| Incyte Corporation | $205.28 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Pfizer INC. | $180.14 | 2021-2025 | |
| Eisai INC. | $177.25 | 2021-2024 | |
| Rigel Pharmaceuticals, INC. | $164.89 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $148.80 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $141.69 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $124.34 | 2021-2025 | Verzenio, Retevmo, Jaypirca |
| Gilead Sciences, INC. | $124.30 | 2021-2024 | |
| Glaxosmithkline, LLC. | $119.13 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $116.52 | 2022-2025 | Iclusig, Alunbrig |
| Sobi, INC | $113.87 | 2022-2024 | |
| Array Biopharma INC | $113.58 | 2021-2024 | Mektovi, Braftovi, Xalkori |
| Springworks Therapeutics, INC. | $109.07 | 2024 | Ogsiveo |
| Genentech USA, INC. | $107.18 | 2021-2025 | Polivy, Phesgo, Itovebi |
| Tersera Therapeutics LLC | $104.38 | 2022-2024 | Zoladex |
| Exelixis INC. | $103.78 | 2021-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $102.90 | 2021-2024 | Onivyde, Tazverik |
| Celgene Corporation | $98.38 | 2022-2025 | Reblozyl |
| Janssen Biotech, INC. | $93.65 | 2021-2025 | Carvykti, Tecvayli, Talvey |
| Abbvie INC. | $85.04 | 2024-2025 | |
| Global Blood Therapeutics, INC. | $69.59 | 2021-2022 | |
| Blueprint Medicines Corporation | $65.17 | 2021-2025 | Ayvakit |
| Chiesi USA, INC. | $57.25 | 2021-2023 | Ferriprox |
| Legend Biotech USA INC. | $52.08 | 2025 | Carvykti |
| Puma Biotechnology, INC. | $44.75 | 2021-2022 | |
| Taiho Oncology, INC. | $43.82 | 2023 | |
| Beone Medicines USA, INC. | $33.75 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $32.76 | 2023 | |
| Organon LLC | $31.10 | 2021-2022 | |
| Geron Corporation | $27.79 | 2025 | Rytelo |
| Mayne Pharma Commercial LLC | $25.15 | 2022 | |
| Servier Pharmaceuticals LLC | $24.58 | 2025 | |
| Agios Pharmaceuticals, INC. | $22.67 | 2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $22.19 | 2024 | Qinlock |
| Karyopharm Therapeutics INC. | $22.05 | 2022 | |
| Mirati Therapeutics, INC. | $20.41 | 2023 | Krazati |
| Adaptive Biotechnologies Corporation | $19.78 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.44 | 2022 | |
| G1 Therapeutics, INC. | $19.34 | 2022 | |
| Tempus Ai, INC | $18.17 | 2024 | |
| Epizyme, INC. | $17.54 | 2021 | |
| Coherus Oncology, INC. | $15.41 | 2025 | Loqtorzi |
| Emmaus Medical, INC. | $13.96 | 2022 | |
| Myovant Sciences INC. | $13.27 | 2021 | |
| Mylan Institutional INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Dacanay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.